Literature DB >> 31067470

Naproxen Exhibits Broad Anti-influenza Virus Activity in Mice by Impeding Viral Nucleoprotein Nuclear Export.

Weinan Zheng1, Wenhui Fan1, Shuang Zhang1, Pengtao Jiao2, Yingli Shang3, Liang Cui4, Madina Mahesutihan4, Jing Li1, Dayan Wang5, George Fu Gao6, Lei Sun7, Wenjun Liu4.   

Abstract

Naproxen is a non-steroidal anti-inflammatory drug that has previously been shown to exert antiviral activity against influenza A virus by inhibiting nucleoprotein (NP) binding to RNA. Here, we show that naproxen is a potential broad, multi-mechanistic anti-influenza virus therapeutic, as it inhibits influenza B virus replication both in vivo and in vitro. The anti-influenza B virus activity of naproxen is more efficient than that of the commonly used neuraminidase inhibitor oseltamivir in mice. Furthermore, the NP of influenza B virus (BNP) has a higher binding affinity to naproxen than influenza A virus NP (ANP). Specifically, naproxen targets the NP at residues F209 (BNP) and Y148 (ANP). This interaction antagonizes the nuclear export of NP normally mediated by the host export protein CRM1. This study reveals a crucial mechanism of broad-spectrum anti-influenza virus activity of naproxen, suggesting that the existing drug naproxen may be used as an anti-influenza drug.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRM1; influenza virus; naproxen; nuclear export; nucleoprotein; vRNP

Mesh:

Substances:

Year:  2019        PMID: 31067470     DOI: 10.1016/j.celrep.2019.04.053

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  17 in total

Review 1.  COVID-19 as an Acute Inflammatory Disease.

Authors:  Rose H Manjili; Melika Zarei; Mehran Habibi; Masoud H Manjili
Journal:  J Immunol       Date:  2020-05-18       Impact factor: 5.422

2.  Synthesis, crystal structure, and a molecular modeling approach to identify effective antiviral hydrazide derivative against the main protease of SARS-CoV-2.

Authors:  Shaaban K Mohamed; Youness El Bakri; Dalia A Abdul; Sajjad Ahmad; Mustafa R Albayati; Chin-Hung Lai; Joel T Mague; Mahmoud S Tolba
Journal:  J Mol Struct       Date:  2022-05-28       Impact factor: 3.841

3.  Anti-Influenza Drug Discovery and Development: Targeting the Virus and Its Host by All Possible Means.

Authors:  Olivier Terrier; Anny Slama-Schwok
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Repurposing Papaverine as an Antiviral Agent against Influenza Viruses and Paramyxoviruses.

Authors:  Megha Aggarwal; George P Leser; Robert A Lamb
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

5.  Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus.

Authors:  Olivier Terrier; Sébastien Dilly; Andrés Pizzorno; Dominika Chalupska; Jana Humpolickova; Evžen Bouřa; Francis Berenbaum; Stéphane Quideau; Bruno Lina; Bruno Fève; Frédéric Adnet; Michèle Sabbah; Manuel Rosa-Calatrava; Vincent Maréchal; Julien Henri; Anny Slama-Schwok
Journal:  Molecules       Date:  2021-04-29       Impact factor: 4.411

6.  Phosphorylation Status of Tyrosine 78 Residue Regulates the Nuclear Export and Ubiquitination of Influenza A Virus Nucleoprotein.

Authors:  Liang Cui; Weinan Zheng; Minghui Li; Xiaoyuan Bai; Wenxian Yang; Jing Li; Wenhui Fan; George Fu Gao; Lei Sun; Wenjun Liu
Journal:  Front Microbiol       Date:  2019-08-07       Impact factor: 5.640

7.  Project IDentif.AI: Harnessing Artificial Intelligence to Rapidly Optimize Combination Therapy Development for Infectious Disease Intervention.

Authors:  Aynur Abdulla; Boqian Wang; Feng Qian; Theodore Kee; Agata Blasiak; Yoong Hun Ong; Lissa Hooi; Falgunee Parekh; Rafael Soriano; Gene G Olinger; Jussi Keppo; Chris L Hardesty; Edward K Chow; Dean Ho; Xianting Ding
Journal:  Adv Ther (Weinh)       Date:  2020-04-16

Review 8.  Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies.

Authors:  Marisa Market; Leonard Angka; Andre B Martel; Donald Bastin; Oladunni Olanubi; Gayashan Tennakoon; Dominique M Boucher; Juliana Ng; Michele Ardolino; Rebecca C Auer
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

Review 9.  Host-Virus Interaction: How Host Cells Defend against Influenza A Virus Infection.

Authors:  Yun Zhang; Zhichao Xu; Yongchang Cao
Journal:  Viruses       Date:  2020-03-29       Impact factor: 5.048

10.  A Quinolinone Compound Inhibiting the Oligomerization of Nucleoprotein of Influenza A Virus Prevents the Selection of Escape Mutants.

Authors:  Juliann Nzembi Makau; Ken Watanabe; Hiroki Otaki; Satoshi Mizuta; Takeshi Ishikawa; Yuji O Kamatari; Noriyuki Nishida
Journal:  Viruses       Date:  2020-03-19       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.